Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ptc Therapeutics (NQ: PTCT )

23.92 -0.90 (-3.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,514,724
Open 24.64
Bid (Size) 23.00 (1)
Ask (Size) 24.80 (22)
Prev. Close 24.82
Today's Range 23.87 - 24.97
52wk Range 23.57 - 56.72
Shares Outstanding 75,344,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for PTC Therapeutics
Via Benzinga
Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37... 
Via Benzinga

Performance

YTD
-37.32%
-37.32%
1 Month
-39.49%
-39.49%
3 Month
-42.33%
-42.33%
6 Month
-45.85%
-45.85%
1 Year
-52.21%
-52.21%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
Via Benzinga
Where PTC Therapeutics Stands With Analysts
Via Benzinga
Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know
Via Benzinga
Micron Technology To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
US Stock Futures Edge Higher Amid Cautious Optimism; Analyst Says How Fed Packages Sept. Pause Key For Market Direction
Via Benzinga
Topics Economy
Exposures Interest Rates
European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Earnings Scheduled For August 3, 2023
Via Benzinga
Where PTC Therapeutics Stands With Analysts
Via Benzinga
Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know
Via Benzinga
What 15 Analyst Ratings Have To Say About PTC Therapeutics
Via Benzinga
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Down Over 1%; US Industrial Output Rises In August
Via Benzinga
Topics Stocks
Exposures US Equities
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Dow Dips 100 Points; US Export Prices Rise 1.3% In August
Via Benzinga
Topics Stocks
Exposures US Equities
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Via InvestorPlace
PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis
Via Benzinga
PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study
Via Benzinga
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.